Reverse acquisition company Hunter Capital RTO1 reported no revenue and a marginal loss in the first quarter of 2026. Profit after financial items amounted to SEK -0.04 million, compared with SEK -0.16 million during the period from the company's formation on August 29 to December 31, 2025. Earnings per share amounted to -0.00094 (-0.0034).Operating profit improved to SEK -0.04 million from SEK -0.16 million. EBITDA amounted to SEK -0.04 million (-0.16). The company had cash and cash equivalents of SEK 0.5 million at the end of the quarter, compared with SEK 0.4 million at the turn of the year.During the quarter, the company received approval for listing on Spotlight Stock Market, where the first trading day was March 6. After the end of the period, the company entered into a letter of intent with the Norwegian biotech company ResoTher Pharma regarding a potential reverse acquisition at an implied valuation of SEK 365-405 million.CEO Jacob Eriksson says that the planned transaction is assessed to be able to create a fully financed and risk-reduced listed biotech company with several clear value drivers. The transaction is conditional on, among other things, due diligence, regulatory approvals, financing and shareholder approvals."In parallel, we continue to evaluate opportunities that can strengthen the company's position and long-term potential. Our ambition remains to act quickly, opportunistically and in a disciplined manner in the work to identify attractive structural transactions where a listed shell can create significant added value for all parties involved," says Eriksson.Hunter Capital RTO1, MkrQ1 2026Revenue0EBITDA-0.04Operating profit-0.04Operating marginProfit before tax-0.04Net profit-0.04Earnings per share-0.00094